Abstracts tagged "Psoriatic arthritis"

Abstract Number: 528 • 2013 ACR/ARHP Annual Meeting
Upregulated Th17 and Innate Pathways Are More Characteristic Of The Skin Than The Synovium In Psoriatic Arthritis
Jennifer Belasco¹, Hiroshi Mitsui¹, Mayte Suarez-Farinas¹, James S. Louie², N. Wei³, Nicholas Gulati¹ and James G. Krueger¹, ¹Krueger Laboratory, The Rockefeller University, New York, NY, ²Rheumatology, UCLA School of Medicine, Los Angeles, CA, ³Arthritis Treatment Center, Frederick, MD
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory joint disease associated with psoriasis. There is little understanding of the relative levels of cytokines and chemokines between…
Abstract Number: 2486 • 2013 ACR/ARHP Annual Meeting
Clinical Performance Of 4 Methods For Detecting Latent Tuberculosis Infection (LTbI) In Patients With Active Chronic Inflammatory Arthritis Taking TNFα Blockers
Carina M F Gomes¹, Maria Teresa Terreri², Maria Isabel Pinto³, Karen Oseki³, Fernanda Spina⁴ and Marcelo M. Pinheiro⁵, ¹Rheumatology Division, Universidade Federal de São Paulo, Sao Paulo, Brazil, ²Pediatrics, Universidade Federal de São Paulo / UNIFESP, Sao Paulo, Brazil, ³Pediatrics, Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁴Rheumatology Division, Universidade Federal de São Paulo Unifesp/EPM, Brazil, Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁵Brazilian Registry of Spondyloarthritis, São Paulo, Brazil
Background/Purpose: About 5% of the Brazilian population has some chronic inflammatory arthropathy (CIA), including rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PA) and juvenile…
Abstract Number: 344 • 2013 ACR/ARHP Annual Meeting
Clinical Phenotype Of Patients With Arthritis Mutilans Has Important Differences Compared To Other Patients With Psoriatic Arthritis
Muhammad Haroon¹, Phil Gallagher² and Oliver FitzGerald¹, ¹Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Rheumatology, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Arthritis mutilans (AM), a severe form of psoriatic arthritis (PsA), is characterised clinically by digital shortening resulting from osteolysis and/or erosions. It is still…
Abstract Number: 2443 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Coronary Heart Disease In Spondyloarthopathies may Be Increased Due To Higher Prevalence Of Risk Factors As Well As The Disease Itself- A Retrospective Analysis At Single VA Medical Center
Trayton Mains¹ and Vikas Majithia², ¹University of Mississippi Medical Center, Jackson, MS, ²G.V. "Sonny" Montogomery VA Medical Center, Jackson, MS
Background/Purpose: An increased prevalence of cardiovascular disease (CVD) and coronary heart disease (CHD) has been reported in patients with spondyloarthritides (SpA). This study investigated the…
Abstract Number: 348 • 2013 ACR/ARHP Annual Meeting
Laboratory Abnormalities In Patients With Psoriatic Arthritis Receiving Apremilast, An Oral Phosphodiesterase 4 Inhibitor: Pooled Safety Analysis Of Three Phase 3, Randomized, Controlled Trials
Philip J. Mease¹, Arthur Kavanaugh², Adewale O. Adebajo³, Juan J. Gomez-Reino⁴, Jürgen Wollenhaupt⁵, Dafna D. Gladman⁶, Maurizio Cutolo⁷, Georg Schett⁸, Eric Lespessailles⁹, Kamal Shah¹⁰, ChiaChi Hu¹⁰, Randall M. Stevens¹⁰, Christopher J. Edwards¹¹ and Charles A. Birbara¹², ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²University of California San Diego, San Diego, CA, ³Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, United Kingdom, ⁴Hospital Clinico Universitario, Santiago, Spain, ⁵Schön Klinik Hamburg-Eilbek, Hamburg, Germany, ⁶University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁷University of Genova, Genova, Italy, ⁸Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁹University of Orléans, Orléans, France, ¹⁰Celgene Corporation, Warren, NJ, ¹¹NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ¹²University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate inflammatory mediators. The PALACE 1, 2, and 3 trials compared the efficacy and…
Abstract Number: 2348 • 2013 ACR/ARHP Annual Meeting
Long Term Safety Of Intravenous Golimumab and Comparisons With Subcutaneous Golimumab In Rheumatologic Conditions: Results From The 120-Day Safety Report Of a Phase 3 Trial Of Intravenous Golimumab
Rene Westhovens¹, Clifton O. Bingham III², Michael E. Weinblatt³, Roy Fleischmann⁴, Edward C. Keystone⁵, Elizabeth C. Hsia⁶, Benjamin Hsu⁶, Lilianne Kim⁶, Surekha Mudivarthy⁶, Michael Mack⁷, Neil Goldstein⁶, Jürgen Braun⁸, Arthur Kavanaugh⁹, Alan M. Mendelsohn¹⁰ and Jonathan Kay¹¹, ¹Rheumatology, University Hospital KU Leuven, Leuven, Belgium, ²Rheumatology, Johns Hopkins University, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴University of Texas Southwestern Medical Center, Dallas, TX, ⁵Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Janssen Research & Development, LLC., Spring House, PA, ⁷Biostatistics, Janssen Research & Development, LLC., Spring House, PA, ⁸PsAID taskforce, EULAR, Zurich, Switzerland, ⁹University of California San Diego, San Diego, CA, ¹⁰Immunology, Janssen Research & Development, LLC., Spring House, PA, ¹¹UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA
Background/Purpose: To describe safety profile of IV GLM in RA from the Ph3 GLM IV program. AE rates of interest are indirectly compared to…
Abstract Number: 350 • 2013 ACR/ARHP Annual Meeting
Cortical Bone Density As Measured By Digital X-Ray Radiogrammetry Correlates with Radiographic Joint Damage In The Hands Within 1 Year In Psoriatic Arthritis
Agnes Szentpetery¹, Muhammad Haroon², Phil Gallagher³, Eric J. Heffernan⁴ and Oliver FitzGerald², ¹Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ³Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁴Radiology, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Structural destruction in peripheral joints may occur over time in both PsA and RA. We previously reported that 47% of early PsA patients treated…
Abstract Number: 2225 • 2013 ACR/ARHP Annual Meeting
COVA322: A Novel, Bispecific Tumor-Necrosis-Factor-Alpha / Interleukin-17A (TNF/IL-17A) Inhibitor With Excellent Pharmacokinetic Properties In Mice and Cynomolgus Monkeys
Mathias Locher, Dragan Grabulovski, Isabella Attinger-Toller, Susann Koenig-Friedrich, Ulrike von der Bey and Julian Bertschinger, Covagen AG, Schlieren, Switzerland
Background/Purpose: The generation of bispecific antibody molecules with excellent biophysical and pharmacokinetic properties has been a challenging task in the past. We present here COVA322,…
Abstract Number: 354 • 2013 ACR/ARHP Annual Meeting
Disease Burden Among Patients With Psoriatic Arthritis Who Have Experienced First Line Tumor Necrosis Factor Inhibitor Regimen Failure In The European Union
Siva Narayanan¹, Yao Lu², Richard Hutchings² and Amanda Baskett², ¹Evidence Generation, Value and Access Center, Ipsos Healthcare, Columbia, MD, ²Ipsos Healthcare, London, United Kingdom
Background/Purpose: Data on second line biologic patients who have experienced 1st line tumor necrosis factor inhibitor (TNF) failure and associated disease burden among patients (pts)…
Abstract Number: 1553 • 2013 ACR/ARHP Annual Meeting
Responsiveness Of Health Related Quality Of Life Questionnaires To Treatment With Anti-TNF Therapy In Psoriatic Arthritis
Zahi Touma¹, Arane Thavaneswaran¹, Vinod Chandran² and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Patient-reported outcomes (PRO) on Health Related Quality of Life (HRQoL) are increasingly used to assess responsiveness after treatment. This study aimed to determine the…
Abstract Number: 326 • 2013 ACR/ARHP Annual Meeting
Reduction Of Disease Burden On Workplace and Household Productivity In Psoriatic Arthritis Over 48 Weeks Of Treatment With Certolizumab Pegol
Arthur Kavanaugh¹, Dafna D. Gladman², Désirée M. van der Heijde³, Oana Purcaru⁴ and Philip J. Mease⁵, ¹Division of Rheumatology Allergy and Immunology, University of California San Diego, San Diego, CA, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴UCB Pharma, Brussels, Belgium, ⁵Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Compared to the general population, patients (pts) with psoriatic arthritis (PsA) suffer greater amounts of disability and substantially lower employment rates.1 To date there…
Abstract Number: 2611 • 2012 ACR/ARHP Annual Meeting
Do Patients with Psoriatic Arthritis Fall Into Distinct Clinical Sub-Groups- a Cluster Analysis?
Arane Thavaneswaran¹, Vinod Chandran² and Dafna D. Gladman³, ¹Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: To determine if demographic and disease characteristics of patients with PsA at presentation to a PsA clinic cluster into distinct groups. Methods: 1058 patients…
Abstract Number: 581 • 2012 ACR/ARHP Annual Meeting
Examining a Role for Th17 Regulation and Toll-Like Receptor Signaling in Psoriatic Arthritis
Fatima Abji¹, Remy Pollock², Fawnda Pellett³, Vinod Chandran⁴ and Dafna D. Gladman², ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a seronegative inflammatory arthritis that develops in 30% of patients with cutaneous psoriasis (PsC). Joint inflammation in PsA is mediated…
Abstract Number: 2557 • 2012 ACR/ARHP Annual Meeting
Ustekinumab in Active Psoriatic Arthritis Including Patients Previously Treated with Anti-TNF Agents: Results of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study
Christopher T. Ritchlin¹, Alice B. Gottlieb², Iain B. McInnes³, Lluis Puig⁴, Proton Rahman⁵, Shu Li⁶, Yuhua Wang⁶, Mittie K. Doyle⁷, Alan Mendelsohn⁸ and Arthur Kavanaugh⁹, ¹Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ²Tufts Medical Center, Boston, MA, ³University of Glasgow, Glasgow, United Kingdom, ⁴Universitat Autònoma de Barcelona, ⁵Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁶Janssen Research and Development, LLC, PA, ⁷Janssen Research and Development, LLC/U of Penn, Spring House/Phila, PA, ⁸Immunology, Janssen Research & Development, LLC, Spring House, PA, ⁹UCSD School of Medicine, La Jolla, CA
Ustekinumab in active psoriatic arthritis including patients previously treated with anti-TNF agents: Results of a Phase 3, multicenter, double-blind, placebo-controlled studyBackground/Purpose: Assess efficacy & safety…
Abstract Number: 590 • 2012 ACR/ARHP Annual Meeting
The Association Between KIR3DL1 Alleles and Psoriatic Arthritis
Remy Pollock¹, Jeffrey Berinstein², Arane Thavaneswaran², Fawnda Pellett³, Dafna D. Gladman⁴ and Vinod Chandran⁵, ¹Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁵Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Killer-cell immunoglobulin-like receptors (KIRs) are activating and inhibitory receptors that regulate NK and NK-T cells, which have been found in psoriatic plaques and synovial…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].